NCT05692024View on ClinicalTrials.gov

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 1, 2027

Conditions
Colorectal CancerCoffeeGastrointestinal MicrobiomeStenosisFibrosis, LiverUltrasound ElastographyProton Magnetic Resonance Spectroscopy
Interventions
DRUG

Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.

Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.

DRUG

Placebo

Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.

Trial Locations (1)

02115

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER